Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality

2016 ◽  
Vol 10 (6) ◽  
pp. 883-892 ◽  
Author(s):  
Do Young Kim ◽  
Kwang-Hyub Han
Keyword(s):  
Hepatocellular Carcinoma ◽  
Treatment Modality ◽  
Transarterial Chemoembolization ◽  
Transarterial Radioembolization

scholarly journals Yttrium-90 Microspheres for Intermediate- or Advanced-Stage Hepatocellular Carcinoma

2021 ◽  
Vol 1 (3) ◽  
Author(s):  
Calvin Young ◽  
Anusree Subramonian ◽  
Charlene Argáez
Keyword(s):  
Hepatocellular Carcinoma ◽  
Adverse Events ◽  
Transarterial Chemoembolization ◽  
Systemic Treatment ◽  
Cost Effective ◽  
Economic Evaluations ◽  
Advanced Stage ◽  
Transarterial Radioembolization ◽  
90Y Microspheres ◽  
Yttrium 90

Transarterial radioembolization using yttrium-90 (90Y) microspheres is a therapeutic option for patients with intermediate- or advanced-stage hepatocellular carcinoma, including those with recurrent or inoperable hepatocellular carcinoma. Overall, the evidence suggests that patients treated with 90Y-based transarterial radioembolization may experience no difference in overall survival, progression-free survival, and tumour response when compared to patients who received transarterial chemoembolization therapies or systemic treatment with sorafenib or lenvatinib. Patients treated with transarterial radioembolization generally experienced similar rates of adverse events compared to those treated with transarterial chemoembolization, although there were some instances where treatment with transarterial radioembolization led to increased or decreased risks of specific adverse events. The comparative safety of transarterial radioembolization versus systemic treatment with sorafenib was unclear as the included studies did not statistically compare the risks of experiencing adverse events. Evidence regarding the cost-effectiveness of 90Y microspheres for treating hepatocellular carcinoma is conflicting. Three economic evaluations suggest treatment with transarterial radioembolization is likely to be cost-effective or dominant — less costly and more effective — compared to transarterial chemoembolization or systemic therapies, while a single economic study suggested treatment with sorafenib or lenvatinib is most likely to be cost-effective or dominant compared to transarterial radioembolization.

Mo1501 Similar Transplant-Free Survival With Transarterial Chemoembolization (TACE) Versus Transarterial Radioembolization (TARE) in Patients With Hepatocellular Carcinoma

2016 ◽  
Vol 150 (4) ◽  
pp. S1132-S1133
Author(s):  
Divya Bhatt ◽  
Amitkumar Patel ◽  
Stacy Achdjian ◽  
Meera Ramanathan ◽  
Layth AL-Jashaami ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Transarterial Chemoembolization ◽  
Free Survival ◽  
Transarterial Radioembolization
Sign in / Sign up

Export Citation Format

Share Document